The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Glioblastoma Multiforme Treatment (GBM)-Global Market Insights and Sales Trends 2024
Synopsis
The global Glioblastoma Multiforme Treatment (GBM) market size is expected to reach US$ 996.4 million by 2029, growing at a CAGR of 8.8% from 2023 to 2029. The market is mainly driven by the significant applications of Glioblastoma Multiforme Treatment (GBM) in various end use industries. The expanding demands from the Hospital & Clinic, ASCs and Others,, are propelling Glioblastoma Multiforme Treatment (GBM) market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Radiotherapy segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Glioblastoma Multiforme Treatment (GBM) market, driven by demand from China, the second largest economy with some signs of stabilising, the Glioblastoma Multiforme Treatment (GBM) market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Glioblastoma Multiforme Treatment (GBM), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Glioblastoma Multiforme Treatment (GBM) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Glioblastoma Multiforme Treatment (GBM) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Glioblastoma Multiforme Treatment (GBM) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Glioblastoma Multiforme Treatment (GBM) covered in this report include Merck, Teva Pharmaceutical, Arbor Pharmaceuticals, Sun Pharmaceutical and Roche, etc.
The global Glioblastoma Multiforme Treatment (GBM) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
Teva Pharmaceutical
Arbor Pharmaceuticals
Sun Pharmaceutical
Roche
Global Glioblastoma Multiforme Treatment (GBM) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Glioblastoma Multiforme Treatment (GBM) market, Segment by Type:
Chemotherapy
Radiotherapy
Gene therapy
Molecular biotechnology
Global Glioblastoma Multiforme Treatment (GBM) market, by Application
Hospital & Clinic
ASCs
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Glioblastoma Multiforme Treatment (GBM) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Glioblastoma Multiforme Treatment (GBM) market size is expected to reach US$ 996.4 million by 2029, growing at a CAGR of 8.8% from 2023 to 2029. The market is mainly driven by the significant applications of Glioblastoma Multiforme Treatment (GBM) in various end use industries. The expanding demands from the Hospital & Clinic, ASCs and Others,, are propelling Glioblastoma Multiforme Treatment (GBM) market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Radiotherapy segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Glioblastoma Multiforme Treatment (GBM) market, driven by demand from China, the second largest economy with some signs of stabilising, the Glioblastoma Multiforme Treatment (GBM) market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Glioblastoma Multiforme Treatment (GBM), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Glioblastoma Multiforme Treatment (GBM) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Glioblastoma Multiforme Treatment (GBM) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Glioblastoma Multiforme Treatment (GBM) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Glioblastoma Multiforme Treatment (GBM) covered in this report include Merck, Teva Pharmaceutical, Arbor Pharmaceuticals, Sun Pharmaceutical and Roche, etc.
The global Glioblastoma Multiforme Treatment (GBM) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
Teva Pharmaceutical
Arbor Pharmaceuticals
Sun Pharmaceutical
Roche
Global Glioblastoma Multiforme Treatment (GBM) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Glioblastoma Multiforme Treatment (GBM) market, Segment by Type:
Chemotherapy
Radiotherapy
Gene therapy
Molecular biotechnology
Global Glioblastoma Multiforme Treatment (GBM) market, by Application
Hospital & Clinic
ASCs
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Glioblastoma Multiforme Treatment (GBM) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Glioblastoma Multiforme Treatment (GBM)
1.1 Glioblastoma Multiforme Treatment (GBM) Market Overview
1.1.1 Glioblastoma Multiforme Treatment (GBM) Product Scope
1.1.2 Glioblastoma Multiforme Treatment (GBM) Market Status and Outlook
1.2 Global Glioblastoma Multiforme Treatment (GBM) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Glioblastoma Multiforme Treatment (GBM) Market Size by Region (2018-2029)
1.4 Global Glioblastoma Multiforme Treatment (GBM) Historic Market Size by Region (2018-2023)
1.5 Global Glioblastoma Multiforme Treatment (GBM) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Glioblastoma Multiforme Treatment (GBM) Market Size (2018-2029)
1.6.1 North America Glioblastoma Multiforme Treatment (GBM) Market Size (2018-2029)
1.6.2 Europe Glioblastoma Multiforme Treatment (GBM) Market Size (2018-2029)
1.6.3 Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Market Size (2018-2029)
1.6.4 Latin America Glioblastoma Multiforme Treatment (GBM) Market Size (2018-2029)
1.6.5 Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Size (2018-2029)
2 Glioblastoma Multiforme Treatment (GBM) Market by Type
2.1 Introduction
2.1.1 Chemotherapy
2.1.2 Radiotherapy
2.1.3 Gene therapy
2.1.4 Molecular biotechnology
2.2 Global Glioblastoma Multiforme Treatment (GBM) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Glioblastoma Multiforme Treatment (GBM) Historic Market Size by Type (2018-2023)
2.2.2 Global Glioblastoma Multiforme Treatment (GBM) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Glioblastoma Multiforme Treatment (GBM) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Glioblastoma Multiforme Treatment (GBM) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Glioblastoma Multiforme Treatment (GBM) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue Breakdown by Type (2018-2029)
3 Glioblastoma Multiforme Treatment (GBM) Market Overview by Application
3.1 Introduction
3.1.1 Hospital & Clinic
3.1.2 ASCs
3.1.3 Others
3.2 Global Glioblastoma Multiforme Treatment (GBM) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Glioblastoma Multiforme Treatment (GBM) Historic Market Size by Application (2018-2023)
3.2.2 Global Glioblastoma Multiforme Treatment (GBM) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Glioblastoma Multiforme Treatment (GBM) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Glioblastoma Multiforme Treatment (GBM) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Glioblastoma Multiforme Treatment (GBM) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Glioblastoma Multiforme Treatment (GBM) Revenue Breakdown by Application (2018-2029)
4 Glioblastoma Multiforme Treatment (GBM) Competition Analysis by Players
4.1 Global Glioblastoma Multiforme Treatment (GBM) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Glioblastoma Multiforme Treatment (GBM) as of 2022)
4.3 Date of Key Players Enter into Glioblastoma Multiforme Treatment (GBM) Market
4.4 Global Top Players Glioblastoma Multiforme Treatment (GBM) Headquarters and Area Served
4.5 Key Players Glioblastoma Multiforme Treatment (GBM) Product Solution and Service
4.6 Competitive Status
4.6.1 Glioblastoma Multiforme Treatment (GBM) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Merck
5.1.1 Merck Profile
5.1.2 Merck Main Business
5.1.3 Merck Glioblastoma Multiforme Treatment (GBM) Products, Services and Solutions
5.1.4 Merck Glioblastoma Multiforme Treatment (GBM) Revenue (US$ Million) & (2018-2023)
5.1.5 Merck Recent Developments
5.2 Teva Pharmaceutical
5.2.1 Teva Pharmaceutical Profile
5.2.2 Teva Pharmaceutical Main Business
5.2.3 Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Products, Services and Solutions
5.2.4 Teva Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Revenue (US$ Million) & (2018-2023)
5.2.5 Teva Pharmaceutical Recent Developments
5.3 Arbor Pharmaceuticals
5.3.1 Arbor Pharmaceuticals Profile
5.3.2 Arbor Pharmaceuticals Main Business
5.3.3 Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Products, Services and Solutions
5.3.4 Arbor Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Revenue (US$ Million) & (2018-2023)
5.3.5 Sun Pharmaceutical Recent Developments
5.4 Sun Pharmaceutical
5.4.1 Sun Pharmaceutical Profile
5.4.2 Sun Pharmaceutical Main Business
5.4.3 Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Products, Services and Solutions
5.4.4 Sun Pharmaceutical Glioblastoma Multiforme Treatment (GBM) Revenue (US$ Million) & (2018-2023)
5.4.5 Sun Pharmaceutical Recent Developments
5.5 Roche
5.5.1 Roche Profile
5.5.2 Roche Main Business
5.5.3 Roche Glioblastoma Multiforme Treatment (GBM) Products, Services and Solutions
5.5.4 Roche Glioblastoma Multiforme Treatment (GBM) Revenue (US$ Million) & (2018-2023)
5.5.5 Roche Recent Developments
6 North America
6.1 North America Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Glioblastoma Multiforme Treatment (GBM) Market Dynamics
11.1 Glioblastoma Multiforme Treatment (GBM) Industry Trends
11.2 Glioblastoma Multiforme Treatment (GBM) Market Drivers
11.3 Glioblastoma Multiforme Treatment (GBM) Market Challenges
11.4 Glioblastoma Multiforme Treatment (GBM) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
